Delving into the Latest Updates on Measles and rubella combined vaccine(Beijing Minhai Biological Technology Co., Ltd.) with Synapse

Overview

Basic Info

Drug Type

Combination vaccine, Live attenuated vaccine, Prophylactic vaccine

Synonyms

Lyophilised live attenuated measles and rubella combined vaccine - Beijing Minhai Biotechnology, MR attenuated combined vaccine, MR attenuated combined vaccine - Beijing Minhai Biotechnology

+ [1]

Target-

Action

stimulants

Mechanism

Immunostimulants

Therapeutic Areas

Infectious DiseasesOther DiseasesMouth and Tooth Diseases

Active Indication

MeaslesRubellaChickenpox+ [1]

Inactive Indication-

Originator Organization

Beijing Minhai Biological Technology Co., Ltd.

Active Organization

Beijing Minhai Biological Technology Co., Ltd.

Shenzhen Kangtai Biological Products Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

China (30 Oct 2012),

MeaslesRubella

Regulation-

Login to view timeline

We investigated the antibody responses and clinical adverse reactions after immunization with live combined measles and rubella vaccine (HF vaccine) in 442 healthy children, aged 12-90 months of age. We obtained 368 paired sera. Among them, 363 were initially sero-negative against measles virus and 343 (94.5%) became sero-positive after immunization. Sero-conversion against rubella virus was demonstrated in 349 (96.7%) of 361 initially sero-negatives against rubella virus. We investigated the clinical adverse reactions in 406 recipients. In 102 (25.1%) recipients, febrile reaction (> 37.5 C) developed on the day 6.7 of vaccination on average, with a mean duration of 2.2 days. Only two (0.5%) developed high body temperature over 39.5 C. Skin rash was noted in 87 (21.4%) on day 7.1 of vaccination on average, with a mean duration of 4.8 days. Lymphoadenopathy was demonstrated in 12 (3.0%). Thus, measles and rubella combined vaccine was safe and sufficiently immunogenic as well as each monovalent one, having clinical advantage in immunization practice.

100 Deals associated with Measles and rubella combined vaccine(Beijing Minhai Biological Technology Co., Ltd.)

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	J07BD53	-

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Measles	China	Beijing Minhai Biological Technology Co., Ltd.	30 Oct 2012
Rubella	China	Beijing Minhai Biological Technology Co., Ltd.	30 Oct 2012

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chickenpox	Preclinical	China	Shenzhen Kangtai Biological Products Co., Ltd.	30 Jan 2022
Mumps	Preclinical	China	Shenzhen Kangtai Biological Products Co., Ltd.	30 Jan 2022